Innovative Nanobody Targeting E1 and E2 Glycoproteins for Chikungunya Virus Infection

VHH-P706 is a humanized nanobody program designed to specifically target the E1 and E2 spike glycoproteins of the chikungunya virus, including the Chikungunya virus complete genome E2 protein (E2). Currently in the Biological Testing stage, this therapeutic candidate leverages advanced antibody engineering to provide high specificity and potential efficacy for the treatment of chikungunya virus infection. By focusing on the viral structural proteins that play essential roles in virus entry and fusion, VHH-P706 aims to offer a novel therapeutic solution for this debilitating infectious disease, providing new hope where conventional antiviral therapies have limited impact.

Licensing Opportunity

VHH-P706 is open for out-licensing and strategic partnerships. We welcome collaboration opportunities with industry partners seeking innovative antiviral therapeutics targeting chikungunya virus infection.

Development Phase

Modality

VHH-P706 utilizes a llama-derived single domain antibody format, commonly referred to as a nanobody. This modular structure results in significantly lower molecular weight compared to conventional antibodies, enabling enhanced tissue penetration and access to cryptic epitopes found on viral targets. The inherent stability and solubility of the nanobody format allow for flexible administration possibilities and robust performance under a wide range of physiological conditions. For chikungunya virus infection, these properties may translate to improved targeting of viral particles in hard-to-reach tissues, providing a competitive edge over traditional full-length antibodies.

Target

E1 Glycoprotein and E2 Glycoprotein are critical envelope proteins expressed on the surface of the chikungunya virus. Both E1 Glycoprotein and E2 Glycoprotein are key molecular components that mediate viral attachment, fusion, and entry into host cells. These glycoproteins are primarily presented on infected host cell membranes and viral particles circulating within the host. As validated targets in chikungunya virus infection, the inhibition of E1 Glycoprotein and E2 Glycoprotein can potentially prevent the virus from successfully invading human cells and propagating infection. By directly targeting both E1 Glycoprotein and E2 Glycoprotein, VHH-P706 strategically addresses essential steps in the viral life cycle, offering strong translational potential and differentiation in the competitive landscape of antiviral therapeutics.

Mechanism of Action

VHH-P706 exerts its therapeutic effect by specifically binding to the structural polyproteins E1 Glycoprotein and E2 Glycoprotein on the chikungunya virus surface. Interference with these glycoproteins is designed to block the conformational changes required for viral fusion and entry into host cells, thereby inhibiting subsequent viral replication and spread. The use of a nanobody platform enables precise targeting while potentially minimizing off-target effects. In addition, this format serves as an adaptable scaffold for advanced modalities, including the development of antibody-drug conjugates, bispecific constructs, or multivalent formulations, further expanding its therapeutic scope in infectious disease management.

Chikungunya Virus Infection

Chikungunya virus infection is an emerging mosquito-borne viral disease that affects millions globally, characterized by sudden-onset fever, joint pain, muscle aches, and long-term arthritis-like symptoms that can persist for months or even years. The disease poses a significant public health challenge in tropical and subtropical regions, especially where control of mosquito vectors is difficult. Currently, there are no specific antiviral drugs for chikungunya virus infection; treatment focuses on symptomatic relief through analgesics and anti-inflammatory medications. This lack of disease-modifying therapies underscores a substantial unmet clinical need, especially during outbreaks where morbidity is high and healthcare systems are strained. VHH-P706 offers the potential for a targeted antiviral approach, aiming to neutralize the virus and mitigate disease progression, thus fulfilling a critical gap in current chikungunya virus management strategies.